crmd_8k.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  March 9, 2015

 
CORMEDIX INC.
 
 
(Exact Name of Registrant as Specified in Charter)
 

Delaware
001-34673
20-5894890
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)

1430 U.S. Highway 206, Suite 200, Bedminster, NJ
07921
(Address of Principal Executive Offices)
(Zip Code)

Registrant’s Telephone Number, Including Area Code: (908) 517-9500
 
745 Route 202-206, Suite 303, Bridgewater, NJ  08807
(Former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act   (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act  (17 CFR 240.13e-4(c))



 
 
 
 
 
Item 3.03 Material Modification to Rights of Security Holders.

On March 9, 2015, we issued a press release to clarify that the extension to April 30, 2015 of the expiration date for our publicly traded warrants is applicable to all of the publicly traded warrants. The expiration date for all publicly traded warrants is now April 30, 2015.
 
A copy of the press release announcing the extension is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
 
Item 9.01 Financial Statements and Exhibits.
 
 
(d)
Exhibits

 
Exhibit No.
Description
 
  
 
 
99.1
Press release dated March 9, 2015.

 
 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
CORMEDIX INC.
 
       
Date: March 9, 2015
By:
/s/ Randy Milby  
    Randy Milby  
    Chief Executive Officer